Investigational drug · Phase 3
JNJ-79635322
Also called: Ramantamig, BCMAxGPRC5DxCD3
Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
7
7 still active
All registered trials
7
Any phase or sponsor naming "JNJ-79635322"
First trial start
2024
Aug 26, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-79635322", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-79635322" as an intervention, largest first.
- A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligiblePivotal-lookingNot yet recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07903272 · 1,000 participants (planned) · Start Dec 14, 2026 · Primary completion Jan 11, 2037
Drug: Ramantamig; Daratumumab and 4 more · For: Multiple Myeloma
- A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07518186 · 700 participants (planned) · Start May 31, 2026 · Primary completion Apr 29, 2029
Drug: JNJ-79635322; Teclistamab · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Springdale, Arkansas · 173 sites in all
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07258511 · 400 participants (planned) · Start Feb 4, 2026 · Primary completion Dec 12, 2028
Drug: JNJ-79635322; Teclistamab · For: Multiple Myeloma
Sites: Phoenix, Arizona; Little Rock, Arkansas; Duarte, California · 157 sites in all
- A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07589634 · 230 participants (planned) · Start Jun 30, 2026 · Primary completion Dec 31, 2027
Drug: Ramantamig; Tocilizumab and 1 more · For: Multiple Myeloma
Sites: Goodyear, Arizona; Beverly Hills, California; Irvine, California · 60 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05652335 · 180 participants (planned) · Start Nov 22, 2022 · Primary completion Apr 19, 2027
Drug: JNJ-79635322 · For: Relapsed or Refractory Multiple Myeloma; Previously Treated Amyloid Light-chain (AL) Amyloidosis
Sites: Duarte, California; Irvine, California; San Francisco, California · 29 sites in all
- A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07266441 · 168 participants · Start Feb 8, 2026 · Primary completion Jun 14, 2027
Drug: JNJ-79635322 · For: Multiple Myeloma
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 71 sites in all
University of Heidelberg Medical CenterAcademic, hospital or other
NCT05695508 · 160 participants (planned) · Start Dec 1, 2022 · Primary completion Sep 15, 2028
Drug: Teclistamab (Tec); Daratumumab and 5 more · For: Multiple Myeloma
Sites: Berlin, Germany; Chemnitz, Germany; Dresden, Germany · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma.
O'Neill C, Broekmans MEC, Korst CLBM, et al. · Hemasphere 2026
- Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape.
van de Donk NWCJ, Sonneveld P, Einsele H · Blood 2026
- Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
Pillarisetti K, Yang D, Luistro L, et al. · Blood 2026
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.